Cardiovascular Hazards of Abacavir- Versus Tenofovir-Containing Antiretroviral Therapies: Insights From an Analysis of the REPRIEVE Trial Cohort

By sjmartinez • April 10, 2025

Davies Smith E, Malvestutto C, Ribaudo HJ, Fichtenbaum CJ, Aberg JA, Watanabe M, Bloomfield GS, Currier JS, Chu SM, Fitch KV, Diggs MR, Bedimo R, Valencia J, Gomez-Ayerbe C, Brar I, Madruga JV, Lu MT, Douglas PS, Zanni MV, Grinspoon SK. Cardiovascular Hazards of Abacavir- Versus Tenofovir-Containing Antiretroviral Therapies: Insights From an Analysis of the REPRIEVE Trial Cohort. Open Forum Infect Dis. 2025 Mar 21;12(4):ofaf177. doi: 10.1093/ofid/ofaf177. PMID: 40207047; PMCID: PMC11979587.

Tags: abacavir, antiretroviral therapy, Infectious Diseases, major adverse cardiovascular events, Publications, REPRIEVE, Tenofovir

The association between cannabis use and electrocardiographic abnormalities in people living with HIV

Larson ME, Pan Y, Lakhani F, Chavez J, Santana A, Nogueira NF, Lieberman A, Riley ED, Wu KC, Tien P, Kizer J, Floris-Moore M, Pyslar[...]

Invasive Cutaneous Mucormycosis in a Patient With Chronic Lymphocytic Leukemia on Obinutuzumab, Idelalisib, and Bruton Tyrosine Kinase Degrader: A Case Report

Morinishi CD, Brown CE, Younes R. Invasive Cutaneous Mucormycosis in a Patient With Chronic Lymphocytic Leukemia on Obinutuzumab, Idelalisib, and Bruton Tyrosine Kinase Degrader: A[...]

Association between postdischarge antibiotic use and C. difficile testing as a surrogate for clinically significant diarrhea

Livorsi DJ, Merchant J, Cho H, Goetz MB, Alexander B, Goto M. Association between postdischarge antibiotic use and C. difficile testing as a surrogate for clinically significant[...]